Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6166 to 6180 of 8213 results

  1. Pulmonary hypertension in neonates: sildenafil (ESUOM51)

    This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.

    Evidence summary
    Published
    29 March 2016

  2. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  3. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Evidence summary
    Published
    11 March 2014

  4. Transient ischaemic attack: clopidogrel (ESUOM23)

    This evidence summary has been withdrawn and NICE accredited guidance is available from the Royal College of Physicians.

    Evidence summary
    Published
    13 December 2013

  5. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    6 January 2014

  6. Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

    This evidence summary has been withdrawn because the product has been discontinued in the UK.

    Evidence summary
    Published
    20 February 2014

  7. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

    Evidence summary
    Published
    25 February 2014

  8. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

    Highly specialised technologies guidance
    Published
    20 July 2016

  9. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

    This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

    Highly specialised technologies guidance
    Published
    16 December 2015

  10. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

    Highly specialised technologies guidance
    Published
    2 August 2017

  11. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Evidence summary
    Published
    2 April 2013

  12. Fatigue in multiple sclerosis: modafinil (ESUOM9)

    This advice has been updated and replaced by NICE guideline NG220.

    Evidence summary
    Published
    2 April 2013

  13. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)

    This guideline has been updated and replaced by NICE guideline NG131.

    Diagnostics guidance
    Published
    3 June 2015

  14. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system) (DG21)

    This guidance has been updated and replaced by NICE technology appraisal guidance 943.

    Diagnostics guidance
    Published
    12 February 2016

  15. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG590)

    This guidance has been updated and replaced by NICE interventional procedures guidance 752.

    Interventional procedures guidance
    Published
    23 August 2017